GSWM
CRDF icon

Golden State Wealth Management’s Cardiff Oncology CRDF Stock Holding History

Golden State Wealth Management’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.16K Buy
+7,050
New +$11.2K ﹤0.01% 1135

Other funds holding CRDF

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
CWP
Curated Wealth Partners El Segundo, California $774M AUM 5.71% 1-Year Est. Return
PRTG
Post Resch Tallon Group Pittsford, New York $145M AUM 25.19% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
SA
Scarborough Advisors Annapolis, Maryland $871M AUM 21.96% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
LWA
Ledgewood Wealth Advisors Exeter, New Hampshire $188M AUM 18.45% 1-Year Est. Return
SNB
Security National Bank Omaha, Nebraska $838M AUM 39.07% 1-Year Est. Return
TCOT
Trust Company of Toledo Holland, Ohio $1.2B AUM 33.38% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Golden State Wealth Management's CRDF Position: Q2 2026 in Review

Golden State Wealth Management opened a new position in Cardiff Oncology (CRDF) in Q2 2026: 7,050 shares worth $9.16K. The stake represents ﹤0.01% of the portfolio and ranks #1135 among its holdings.

16 funds tracked by Wall St. Rank hold CRDF as of Q2 2026.

  • Golden State Wealth Management held 7,050 shares of Cardiff Oncology worth $9.16K as of Q2 2026.
  • Cardiff Oncology was a new Golden State Wealth Management position in Q2 2026.
  • Cardiff Oncology made up ﹤0.01% of Golden State Wealth Management's portfolio in Q2 2026, its #1135 holding.
  • 16 funds tracked by Wall St. Rank held Cardiff Oncology as of Q2 2026.

Based on Golden State Wealth Management's 13F filing for Q2 2026, filed 22 Jul 2026.